{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T05:08:11Z","timestamp":1780463291704,"version":"3.54.1"},"reference-count":56,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:00:00Z","timestamp":1780444800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Zoledronic acid (ZOL), a potent bisphosphonate, is increasingly used off-label in pediatric bone disorders, but its long-term effects on the growing skeleton remain underexplored. This study aimed to investigate the impact of ZOL dose, treatment duration, and age at treatment initiation on femoral structure and mechanical properties in growing rice rats, addressing a critical knowledge gap.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Two complementary preclinical studies were performed in female rice rats. Study 1 examined dose-dependent effects by administering ZOL (0, 8, 20, 50, 125 \u00b5g\/kg) every 4 weeks, starting at age 4 weeks, for up to 30 weeks. Study 2 investigated age at treatment initiation (4, 16, or 22 weeks) and durations (6, 12, or 18 weeks) using a single oncologic dose of ZOL (80 \u00b5g\/kg every 4 weeks). Femoral cancellous and cortical pQCT assessed bone mineral content (BMC), volumetric bone mineral density (vBMD), area and microstructure. 3-point bending of the femoral diaphysis was used to determine biomechanical properties.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>ZOL increased total metaphyseal BMC, vBMD, and area, with oncologic doses (20-125 \u00b5g\/kg) producing 15-25% greater increases in metaphyseal BMC than the osteoporosis dose (8 \u00b5g\/kg) after 18\u201330 weeks of treatment. Cortical parameters (area and periosteal circumference) and mid-diaphyseal mechanical properties (ultimate load, moment of inertia) also increased when treatment began in young, growing rats and was maintained for 18\u201324 weeks, although clear dose\u2013response effects were limited. When ZOL started later, skeletal responses were attenuated and required longer treatment durations to become significant.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>ZOL enhances metaphyseal and cortical bone properties while improving mechanical strength, particularly when treatment is initiated at an early age. The skeletal response depends on both duration and age at initiation. Notably, ZOL dose-response effects are pronounced in cancellous bone. Cortical structural and mechanical properties exhibit a nonlinear response, with significant differences observed only at extended treatment durations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2026.1772372","type":"journal-article","created":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T04:48:22Z","timestamp":1780462102000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Dose-, duration- and age-dependent effects of zoledronic acid on bone structure and mechanical properties in growing rice rats"],"prefix":"10.3389","volume":"17","author":[{"given":"J. Ignacio","family":"Aguirre","sequence":"first","affiliation":[{"name":"Department of Physiological Sciences, University of Florida (UF)","place":["Gainesville, FL, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan G.","family":"Messer","sequence":"additional","affiliation":[{"name":"Department of Physiological Sciences, University of Florida (UF)","place":["Gainesville, FL, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelyn J.","family":"Castillo","sequence":"additional","affiliation":[{"name":"Department of Physiological Sciences, University of Florida (UF)","place":["Gainesville, FL, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatilla L.","family":"da Silva Frota Gomes","sequence":"additional","affiliation":[{"name":"Department of Physiological Sciences, University of Florida (UF)","place":["Gainesville, FL, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos A.","family":"Urrego","sequence":"additional","affiliation":[{"name":"Department of Biomedical Engineering, University of Michigan","place":["Ann Arbor, MI, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David H.","family":"Kohn","sequence":"additional","affiliation":[{"name":"Department of Biomedical Engineering, University of Michigan","place":["Ann Arbor, MI, United States"]},{"name":"Department of Biologic and Materials Sciences, University of Michigan","place":["Ann Arbor, MI, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald B.","family":"Kimmel","sequence":"additional","affiliation":[{"name":"Department of Physiological Sciences, University of Florida (UF)","place":["Gainesville, FL, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.4065\/83.9.1032","article-title":"Bisphosphonates: mechanism of action and role in clinical practice","volume":"83","author":"Drake","year":"2008","journal-title":"Mayo Clinic Proc"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(20000615)88:12+<2961::aid-cncr12>3.3.co;2-c","article-title":"Cellular and molecular mechanisms of action of bisphosphonates","volume":"88","author":"Rogers","year":"2000","journal-title":"Cancer"},{"key":"B3","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1517\/13543776.11.9.1371","article-title":"Bisphosphonates: mechanisms of action","volume":"19","author":"Fleisch","year":"1998","journal-title":"Endocr Rev"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2008.12.003","article-title":"Efficacy of bisphosphonates in reducing fracture risk in postmenopausal osteoporosis","volume":"122","author":"Bilezikian","year":"2009","journal-title":"Am J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2011-3060","article-title":"Clinical review. Comparative effectiveness of drug treatments to prevent fragility fractures: a systematic review and network meta-analysis","volume":"97","author":"Murad","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199511303332201","article-title":"Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase Iii Osteoporosis Treatment Study Group","volume":"333","author":"Liberman","year":"1995","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2008-1531","article-title":"Clinical review 1: bisphosphonate use in childhood osteoporosis","volume":"94","author":"Bachrach","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.55275\/jposna-2019-33","article-title":"Pediatric orthopaedics: what do we know after 50 years","volume":"1","author":"Laine","year":"2019","journal-title":"J Pediatr Orthopaedic Soc North America"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz957","article-title":"Alendronate improves bone mineral density in children and adolescents perinatally infected with human immunodeficiency virus with low bone mineral density for age","volume":"71","author":"Jacobson","year":"2020","journal-title":"Clin Infect Dis"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1177\/0961203313503051","article-title":"The incidence, diagnostic clinical manifestations and severity of juvenile systemic lupus erythematosus in New Zealand Maori and Pacific Island children: the Starship experience (2000-2010)","volume":"22","author":"Concannon","year":"2013","journal-title":"Lupus"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.24563","article-title":"Use of zoledronic acid for treatment of chemotherapy related osteonecrosis in children and adolescents: a retrospective analysis","volume":"60","author":"Padhye","year":"2013","journal-title":"Pediatr Blood Cancer"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.21037\/tp.2017.09.10","article-title":"Zoledronic acid in pediatric metabolic bone disorders","volume":"6","author":"Bowden","year":"2017","journal-title":"Transl Pediatr"},{"key":"B13","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s00198-015-3216-9","article-title":"Zoledronic acid in children with osteogenesis imperfecta and Bruck syndrome: a 2-year prospective observational study","volume":"27","author":"Otaify","year":"2016","journal-title":"Osteoporos Int"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgab458","article-title":"Zoledronic acid vs placebo in pediatric glucocorticoid-induced osteoporosis: a randomized, double-blind, phase 3 trial","volume":"106","author":"Ward","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1159\/000512730","article-title":"Outcomes of zoledronic acid use in paediatric conditions","volume":"93","author":"Lim","year":"2020","journal-title":"Horm Res Paediatr"},{"key":"B16","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1159\/000365889","article-title":"The use of bisphosphonates in pediatrics","volume":"82","author":"Baroncelli","year":"2014","journal-title":"Horm Res Paediatr"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.pmrj.2013.10.009","article-title":"Bisphosphonate treatment for children with disabling conditions","volume":"6","author":"Boyce","year":"2014","journal-title":"PM R"},{"key":"B18","doi-asserted-by":"publisher","first-page":"36","DOI":"10.5863\/1551-6776-21.1.36","article-title":"Medication repurposing in pediatric patients: teaching old drugs new tricks","volume":"21","author":"Rumore","year":"2016","journal-title":"J Pediatr Pharmacol Ther"},{"key":"B19","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1186\/s13023-024-03345-0","article-title":"Osteogenesis imperfecta: a study of the patient journey in 13 European countries","volume":"19","author":"Westerheim","year":"2024","journal-title":"Orphanet J Rare Dis"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2009.11.019","article-title":"Higher doses of bisphosphonates further improve bone mass, architecture, and strength but not the tissue material properties in aged rats","volume":"46","author":"Shahnazari","year":"2010","journal-title":"Bone"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1210\/en.2013-1993","article-title":"Effect of bisphosphonates on the rapidly growing male murine skeleton","volume":"155","author":"Zhu","year":"2014","journal-title":"Endocrinology"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s00223-002-2015-4","article-title":"Long-term zoledronic acid treatment increases bone structure and mechanical strength of long bones of ovariectomized adult rats","volume":"72","author":"Hornby","year":"2003","journal-title":"Calcif Tissue Int"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-016-3701-9","article-title":"Zoledronate treatment has different effects in mouse strains with contrasting baseline bone mechanical phenotypes","volume":"27","author":"Aref","year":"2016","journal-title":"Osteoporos Int"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1002\/jor.22343","article-title":"Bisphosphonate-induced reductions in rat femoral bone energy absorption and toughness are testing rate-dependent","volume":"31","author":"Smith","year":"2013","journal-title":"J Orthop Res"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/s0022-3565(25)12261-1","article-title":"Long-term safety of the aminobisphosphonate alendronate in adult dogs. I. General safety and biomechanical properties of bone","volume":"276","author":"Peter","year":"1996","journal-title":"J Pharmacol Exp Ther"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1007\/bf01320915","article-title":"Continuous alendronate treatment throughout growth, maturation, and aging in the rat results in increases in bone mass and mechanical properties","volume":"53","author":"Guy","year":"1993","journal-title":"Calcif Tissue Int"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.29183","article-title":"Effects of zoledronic acid on osteonecrosis and acute lymphoblastic leukemia treatment efficacy in preclinical models","volume":"68","author":"Janke","year":"2021","journal-title":"Pediatr Blood Cancer"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2020.582316","article-title":"Response to zoledronic acid infusion in children with fibrous dysplasia","volume":"8","author":"Tripathy","year":"2020","journal-title":"Front Pediatr"},{"key":"B29","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1016\/j.bone.2009.04.255","article-title":"Systemic effects of zoledronic acid in children with traumatic femoral head avascular necrosis and Legg-Calve-Perthes disease","volume":"45","author":"Johannesen","year":"2009","journal-title":"Bone"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.22681","article-title":"The use of zoledronic acid in pediatric cancer patients","volume":"56","author":"August","year":"2011","journal-title":"Pediatr Blood Cancer"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1097\/00005792-199707000-00005","article-title":"Long-term effects of bisphosphonates on the growing skeleton: studies of young patients with severe osteoporosis","volume":"76","author":"Brumsen","year":"1997","journal-title":"Medicine"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-016-3723-3","article-title":"Osteogenesis imperfecta in children and adolescents-new developments in diagnosis and treatment","volume":"27","author":"Trejo","year":"2016","journal-title":"Osteoporos Int"},{"key":"B33","doi-asserted-by":"publisher","first-page":"99","DOI":"10.6065\/apem.2016.21.2.99","article-title":"A successful treatment of hypercalcemia with zoledronic acid in a 15-year-old boy with acute lymphoblastic leukemia","volume":"21","author":"Park","year":"2016","journal-title":"Ann Pediatr Endocrinol Metab"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1515\/jpem-2013-0244","article-title":"Hypercalcemia and osteolytic lesions as presenting symptoms of acute lymphoblastic leukemia in childhood. The use of zoledronic acid and review of the literature","volume":"27","author":"Kolyva","year":"2014","journal-title":"J Pediatr Endocrinol Metab"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3332\/ecancer.2015.542","article-title":"Hypercalcaemia with disseminated osteolytic lesions: a rare presentation of childhood acute lymphoblastic leukaemia","volume":"9","author":"Lokadasan","year":"2015","journal-title":"Ecancermedicalscience"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2007.05.002","article-title":"Acute phase response and mineral status following low dose intravenous zoledronic acid in children","volume":"41","author":"Munns","year":"2007","journal-title":"Bone"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.1598","article-title":"Zoledronic acid improves bone mineral density in pediatric spinal cord injury","volume":"27","author":"Ooi","year":"2012","journal-title":"J Bone Miner Res"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/0030-4220(56)90249-3","article-title":"Periodontal disease in the rice rat. Ii. Methods for the evaluation of the extent of periodontal disease","volume":"9","author":"Gupta","year":"1956","journal-title":"Oral Surg Oral Med Oral Pathol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.1669","article-title":"Oncologic doses of zoledronic acid induce osteonecrosis of the jaw-like lesions in rice rats (Oryzomys palustris) with periodontitis","volume":"27","author":"Aguirre","year":"2012","journal-title":"J Bone Miner Res"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.archoralbio.2016.10.018","article-title":"Breeding, husbandry, veterinary care, and hematology of marsh rice rats (Oryzomys palustris), a small animal model for periodontitis","volume":"54","author":"Aguirre","year":"2015","journal-title":"J Am Assoc Lab Anim Sci"},{"key":"B41","doi-asserted-by":"publisher","first-page":"S75","DOI":"10.1016\/j.archoralbio.2016.10.018","article-title":"Systemic sclerostin antibody treatment reduces alveolar bone loss in rice rats with active periodontitis","volume":"28","author":"Aguirre","year":"2013","journal-title":"J Bone Miner Res"},{"key":"B42","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.bone.2017.12.025","article-title":"Zoledronic acid increases the prevalence of medication-related osteonecrosis of the jaw in a dose dependent manner in rice rats (Oryzomys palustris) with localized periodontitis","volume":"108","author":"Messer","year":"2018","journal-title":"Bone"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2021.116184","article-title":"Preclinical models of medication-related osteonecrosis of the jaw (Mronj)","volume":"153","author":"Aguirre","year":"2021","journal-title":"Bone"},{"key":"B44","article-title":"Effect of alendronate in a murine model of estrogen deficiency","volume":"19","author":"Gentile","year":"2004","journal-title":"J Bone Miner Res"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2021.116168","article-title":"Biologic and pathologic aspects of osteocytes in the setting of medication-related osteonecrosis of the jaw (Mronj)","volume":"153","author":"Aguirre","year":"2021","journal-title":"Bone"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.071207","article-title":"Long-term protective effects of zoledronic acid on cancellous and cortical bone in the ovariectomized rat","volume":"23","author":"Gasser","year":"2008","journal-title":"J Bone Miner Res"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1111\/odi.13052","article-title":"Zoledronate treatment duration is linked to bisphosphonate-related onj prevalence in rice rats with generalized periodontitis","volume":"25","author":"Messer","year":"2019","journal-title":"Oral Dis"},{"key":"B48","doi-asserted-by":"publisher","first-page":"3133","DOI":"10.1002\/ar.24876","article-title":"Bone structural, biomechanical, and histomorphometric characteristics of the hindlimb skeleton in the marsh rice rat (Oryzomys palustris)","volume":"305","author":"Castillo","year":"2021","journal-title":"Anat Rec (Hoboken)."},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.2001.16.4.765","article-title":"Lasofoxifene (Cp-336,156) protects against the age-related changes in bone mass, bone strength, and total serum cholesterol in intact aged male rats","volume":"16","author":"Ke","year":"2001","journal-title":"J Bone Miner Res"},{"key":"B50","first-page":"69","article-title":"Statistics corner: a guide to appropriate use of correlation coefficient in medical research","volume":"24","author":"Mukaka","year":"2012","journal-title":"Malawi Med J"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.76774","article-title":"The role of the periosteum in bone formation from adolescence to old age","volume":"17","author":"Panagakis","year":"2025","journal-title":"Cureus"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1002\/ar.1091540307","article-title":"Periosteal appositional bone growth from age two to age seventy in man. A tetracycline evaluation","volume":"154","author":"Epker","year":"1966","journal-title":"Anat Rec"},{"key":"B53","first-page":"194","article-title":"Bone growth in length and width: The yin and yang of bone stability","volume":"5","author":"Rauch","year":"2005","journal-title":"J Musculoskelet Neuronal Interact"},{"key":"B54","article-title":"Mechanical basis of bone strength: Influence of bone material, bone structure and muscle action","volume":"17","author":"Hart","year":"2017","journal-title":"J Musculoskelet Neuronal Interact"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1007\/BF02441170","article-title":"Age-related changes in the density and tensile strength of human femoral cortical bone","volume":"27","author":"Wall","year":"1979","journal-title":"Calcif Tissue Int"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1002\/jor.23442","article-title":"Pth(1-34) and zoledronic acid have differing longitudinal effects on juvenile mouse femur strength and morphology","volume":"35","author":"Bartlow","year":"2017","journal-title":"J Orthop Res"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1772372\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T04:48:29Z","timestamp":1780462109000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1772372\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,3]]},"references-count":56,"alternative-id":["10.3389\/fendo.2026.1772372"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1772372","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,3]]},"article-number":"1772372"}}